Emerging treatments in the management of schizophrenia – focus on sertindole by Muscatello, Maria Rosaria A et al.
© 2010 Muscatello et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Drug Design, Development and Therapy 2010:4 187–201
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
187
Review
open access to scientific and medical research
Open Access Full Text Article
DOI:10.2147/DDDT.S6591
emerging treatments in the management  
of schizophrenia – focus on sertindole
Maria Rosaria A Muscatello
Antonio Bruno
Gianluca Pandolfo
Umberto Micò
Salvatore Settineri
Rocco Zoccali
Section of Psychiatry, Department 
of Neurosciences, Psychiatric 
and Anaesthesiological Sciences, 
University of Messina, italy
Correspondence: Rocco Zoccali 
Department of Neurosciences, 
Psychiatric and Anesthesiological 
Sciences, Policlinico Universitario via 
Consolare valeria – Messina 98125 italy 
Tel +090 2221 2092 
Fax +090 695 136 
email rocco.zoccali@unime.it
Abstract: The antipsychotic treatment of schizophrenia is still marked by poor compliance, 
and drug discontinuation; the development of more effective and safer drugs still remains a 
challenge. Sertindole is a second-generation antipsychotic with high affinity for dopamine 
D2, serotonin 5-HT2A, 5-HT2C, and α1-adrenergic receptors, and low affinity for other recep-
tors. Sertindole undergoes extensive hepatic metabolism by the cytochrome P450 isoenzymes 
CYP2D6 and CYP3A4 and has an elimination half-life of approximately three days. In 
controlled clinical trials sertindole was more effective than placebo in reducing positive and 
negative symptoms, whereas it was as effective as haloperidol and risperidone against the 
positive symptoms of schizophrenia. The effective dose-range of sertindole is 12–20 mg, 
administered orally once daily. The most common adverse events are headhache, insomnia, 
rhinitis/nasal congestion, male sexual dysfunction, and moderate weight gain, with few 
extrapyramidal symptoms and metabolic changes. Sertindole is associated with corrected QT 
interval prolongation, with subsequent risk of serious arrythmias. Due to cardiovascular safety 
concerns, sertindole is available as a second-line choice for patients intolerant to at least one 
other antipsychotic agent. Further clinical studies, mainly direct “head-to-head” comparisons 
with other second-generation antipsychotic agents, are needed to define the role of sertindole 
in the treatment of schizophrenia.
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Introduction
Schizophrenia, a severe and debilitating mental illness affecting approximately 1% 
of the population1 is a heterogeneous disorder characterized by positive and negative 
symptoms and often associated with cognitive impairment and affective, mainly 
depressive, symptoms. The course of schizophrenia is chronic, with relapses in 
psychotic episodes, disturbed cognitive functioning, poor quality of life and social 
decline. Psychopharmacological treatments have significantly modified the longitu-
dinal course and outcome of schizophrenia. However, according to Tamminga and 
Holcomb,2 only 10%–20% of patients with schizophrenia show a good outcome, 
recovering to pre-  illness levels of functioning. Another 15%–20% show a poor 
outcome and are considered treatment resistant. The middle group presents residual 
symptoms in several domains of schizophrenia, such as cognitive, psychotic and 
affective symptoms, and impaired socio-occupational functioning despite medica-
tions. Nevertheless, antipsychotic medication is the primary intervention for the 
stabilization of acute psychotic episodes and the prevention of recurrences and relapses 
in patients with schizophrenia. A key feature for therapeutic success is drug safety Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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and tolerability; an incomplete response is often the result 
of poor tolerability because side effects can affect treat-
ment compliance. Safety and tolerability issues range from 
specific, fairly simple adverse events (AEs) to more severe, 
life-threatening conditions such as agranulocytosis, acute 
diabetes and cardiac arrhythmia.
“Atypical” or second-generation antipsychotics, were 
initially said to differ from typical antipsychotics in that 
they do not cause movement disorders (catalepsy) in rats at 
clinically effective doses.3 Over the past decade, they have 
become the treatment of choice for schizophrenia in many 
countries, due to the perception of a more favorable toler-
ability profile, thus raising major hopes of superior effects in 
a number of areas such as compliance, negative symptoms, 
cognitive functioning, movement disorders, and quality of 
life. According to treatment guidelines,4,5 second-generation 
antipsychotics include drugs such as amisulpride, aripip-
razole, clozapine, olanzapine, quetiapine, risperidone, 
sertindole, ziprasidone and zotepine. Besides dopamine 
receptor antagonism, second-generation antipsychotics 
have an additional range of binding profile at other recep-
tor sites, including those for serotonin (5-HT1A, 2A, 2C, 3, 6, 7), 
and norepinephrine (α1 and α2).6 Second-generation antip-
sychotics are characterized by a low propensity to induce 
acute extrapyramidal symptoms and tardive dyskinesia 
and, with the exception of risperidone and amisulpride, by 
a weak potential to cause hyperprolactinemia.7 Neverthe-
less, the safety advantages of the atypical drugs have been 
questioned, as their use is associated with differential risk 
of metabolic effect, such as weight gain, lipid dysregulation 
and hyperglycemia,8 and cardiovascular adverse events, 
particularly prolongation of heart-rate corrected QT interval 
(QTc) of the   electrocardiogram (ECG).9
The Clinical Antipsychotic Trials of Intervention Effec-
tiveness (CATIE) was the first objective comparison of 
multiple antipsychotic drugs carried out with patients in 
settings that were representative of real-world treatment set-
tings for people with schizophrenia. The trial showed that, in 
patients with chronic schizophrenia, antipsychotic treatment 
was marked by poor compliance, drug discontinuation and 
frequent switching due to lack of efficacy. Poor compliance 
equally affected both conventional and atypical antipsy-
chotics, with the exception of olanzapine. Furthermore, it 
confirmed the association between metabolic disorders and 
atypical antipsychotics.10,11
Sertindole is an atypical antipsychotic that was initially 
marketed within the European Union between 1996 and 
1997 for the treatment of schizophrenia. However, data from 
the Adverse Drug Reaction On-line Information Tracking 
(ADROIT) database in the United Kingdom subsequently 
suggested an increase in cardiovascular mortality with 
sertindole compared with other atypical antipsychotics. By 
the end of November 1998, the Committee on Safety of 
Medicines (CSM), and the Medicine Control Agency (MCA) 
had been notified of 36 suspected adverse drug reactions 
with a fatal outcome and 13 reports of serious, even nonfatal 
arrythmias in patients treated with sertindole. This potential 
effect, ascribed to the QT-interval prolongation induced 
by sertindole, led to the suspension of all European Union 
marketing authorizations in 1998, pending a full evaluation 
of its risk-benefit profile. Since then, nonclinical data showed 
that QT-interval prolongation was not related with ventricular 
arrhythmias.12–14 Moreover, results from epidemiological 
studies failed to confirm the ADROIT signal and did not 
indicate an excess of overall mortality with sertindole relative 
to other recently developed antipsychotics.15–17
Based on this evidence, the Committee for Medicinal 
Products for Human Use (CHMP) opted to reintroduce 
sertindole for use in Europe under certain restrictions, such 
as on a named-patient/compassionate use program (NPU) in 
post-marketing surveillance studies. Sertindole was finally 
approved by the European Commission and made available 
in the European market in 2006.
This article analyzes the pharmacological properties, 
clinical efficacy, tolerability and safety profile of sertindole 
in patients with schizophrenia.
Data sources and selection  
of studies
Using the keywords “sertindole”, and “schizophrenia”, a 
literature search was undertaken using the international 
database PubMed, to find all the studies published in English. 
Additional references were identified from the reference 
lists of published articles. Data were also collected from the 
product labelling. Searches were last updated on March 5, 
2010.
Pharmacological profile
Sertindole is a phenylindole derivative (1-[2-[4-[5-chloro-
1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl] ethyl-2-
imidazolidinone). In vitro studies showed that sertindole 
exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, 
dopamine D2, and α1-adrenergic receptors, with binding 
affinities of 0.20, 0.51, 0.45, and 1.4 nmol/, respectively, 
whereas it has a low affinity for cholinergic muscarinic, 
histamine H1, and α2-adrenergic receptors.3,18,19 Moreover, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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sertindole has high 5-HT6 receptor affinity (in vitro binding 
affinity = 9.13 pKi value, -log M).20 Combined dopamine 
D2 and serotonin 5-HT2A receptor antagonism is a feature 
common to most atypical antipsychotics and is thought 
to contribute to their therapeutic effect on schizophrenic 
symptoms.21–23 Results from a positron emission tomogra-
phy (PET) study on healthy subjects showed that sertindole 
up to 12 mg/day induced a 5-HT2A receptor occupancy of 
approximately 100%, thus confirming preclinical data on 
sertindole receptor affinity.24 Biochemical, electrophysi-
ological and behavioral studies in animal models showed 
that sertindole selectively inhibits mesolimbic rather than 
nigrostriatal dopaminergic activity, thus suggesting a low 
potential to induce extrapyramidal symptoms (EPS) when 
compared with conventional antipsychotics.25–27 Another 
PET study on four patients affected by schizophrenia after 
6–8 weeks of treatment with sertindole up to 20 mg/day, 
aimed to investigate the D2 receptor occupancy in striatal and 
extra-striatal regions, evidenced that sertindole was effective 
at relatively low striatal D2 receptor occupancy (52%–68%), 
thus suggesting a low risk for EPS.28
The receptor-affinity profile of sertindole, particularly its 
weak antagonism at cholinergic muscarinic and histaminergic 
H1 receptors, provides an explanation for its beneficial effect 
on cognitive functioning. In animal models, sertindole, and 
also risperidone and clozapine, but not haloperidol, were 
observed to reverse cognitive deficits induced by repeated 
PCP administration measured by the Morris water maze.29 
Moreover, differently from risperidone, olanzapine, and 
clozapine, sertindole induced a significant reversal of impair-
ment in extradimensional set shifting and attentional shifting 
following subchronic PCP administration,30–32 and improves 
subchronic PCP-induced reversal learning and episodic 
memory deficits in rodents.33
Pharmacokinetics
Sertindole is slowly absorbed by the gastrointestinal tract, 
reaching peak concentrations within ten hours after oral doses 
in healthy subjects and renally impaired patients. The relative 
bioavailability of the tablet formulation is about 75% and 
absorption is significantly affected by food or antacids.34–36 
Over the dose range of 4–16 mg/day, dose-proportional 
increases in the maximum plasma concentrations (Cmax) 
[from 2.0 to 9.1 ng/mL] and the area under the plasma 
concentration-time curve (AUC from 170 to 572 ng · h/mL) 
of sertindole have been documented.37 Once absorbed, sertin-
dole readily distributes in tissues, as evidenced by the large 
volume distribution of approximately 20 L/kg; its plasma 
protein binding, mainly to albumin and α1-acid glycoprotein, 
is 99.5%.38 Sertindole readily penetrates both the blood–brain 
and placental barriers because of its basic lipophilic   property; 
however, differently from other antipsychotics, it is not known 
if sertindole acts as a substrate or an inhibitor of the efflux 
transporter P-glycoproteine which is highly expressed in 
the brain, liver, kidney, and gut.39,40 Sertindole undergoes 
extensive metabolism in the liver by the cytochrome P450 
isoenzymes CYP2D6 and CYP3A4, to two main metabo-
lites, dehydrosertindole (via oxidation) and norsertindole 
(via N-dealkylation) with negligible effects in humans. 
Genetic polymorphism of the CYP2D6 isoform leads to a 
moderate interindividual variation in the pharmacokinetics 
of sertindole, with reduction in sertindole clearance up to 
67% and plasma sertindole concentrations 2–3 times higher 
in poor metabolizers (PM, up to 10% of the general popula-
tion) when compared with extensive metabolizers (EM). 
Sertindole and its metabolites are excreted slowly, mainly 
in the feces with a minor amount appearing in the urine. 
Its mean terminal half-life is 53–102 hours, as evidenced 
in single- and multiple-dose studies in healthy subjects;34,35 
therefore, steady-state is reached within 2–3 weeks. The 
relatively long half-life of sertindole in comparison to other 
atypical antipsychotics may represent a potential benefit in 
clinical practice and patient compliance. Neither gender nor 
age seem to affect the pharmacokinetics of sertindole. Nev-
ertheless, slower titration and lower maintenance dose may 
be appropriate in elderly patients who are especially sensitive 
to the hypotensive effects of the drug.35 Dosage adjustment 
is not necessary in patients with mild, moderate, and severe 
renal impairment,36 whereas a dose reduction is required in 
hepatically impaired patients, as the clearance of sertindole 
decreases in this population.
Drug interactions
The importance of CYP2D6 and CYP3A4 in sertindole clear-
ance is underlined by its interactions with potent inhibitors 
of these isoenzymes. Concomitant treatment with fluoxetine, 
paroxetine and quinidine (CYP2D6 inhibitors) and erythro-
mycin, ketoconazole and indinavir (CYP3A4 inhibitors), 
may raise plasma sertindole concentrations. Nevertheless, 
oral coadministration of erythromycin, 250 mg 4 times/day, 
caused a slight increase in plasma AUC of sertindole given 
as a single 4 mg dose to healthy subjects.41 On the other 
hand, plasma sertindole concentrations may decrease during 
concomitant treatment with CYP inducers such as carbam-
azepine, rifampicin, phenobarbital, and phenytoin. Recent 
in vitro biochemical evidence has showed that sertindole, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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which has the lowest inhibitory constant (Ki = 25 µM) among 
the tested drugs (phenotiazines, haloperidol, and risperidone), 
should not inhibit the activity of CYP2C6 when administered 
in vivo.42 Thus, it seems unlikely that sertindole may interfere 
in the biotransformation of concomitantly given medications. 
Formal kinetic studies in healthy volunteers have showed 
that the pharmacokinetic parameters of alprazolam and ter-
fenadine where not significantly affected by the concomitant 
treatment with sertindole, administered at daily doses of 
12 mg and 20 mg, respectively.43,44
Because of the effect on QTc interval, sertindole is con-
traindicated in combination with drugs known to significantly 
increase the QTc interval, such as some antihistamines (ter-
fenadine and astemizole), some antiarrhythmics (amiodarone 
and quinidine), quinolone antibiotics, and many antipsychot-
ics and antidepressants.38
Efficacy
Positive and negative symptoms
The efficacy of sertindole in patients with schizophrenia has 
been established in five randomized, double-blind clinical 
trials (see Table 1), without considering results from smaller 
studies presented as case reports, posters, and proceedings of 
congresses. These studies included one placebo-controlled 
trial,45 three comparisons with haloperidol,46–48 and one with 
risperidone.49 Of the five main published sertindole trials, 
only one evaluated the long-term outcome.48
A randomized, controlled, dose-ranging trial, involv-
ing 205 participants, evaluated the efficacy of sertindole, 
administered at the dosage of 8–20 mg/day for 6–7 weeks, 
in the treatment of schizophrenia. Sertindole at the dose 
of 20 mg/day was more effective than placebo in reducing 
Positive and Negative Syndrome Scale (PANSS), and brief 
Psychiatric Rating Scale (BPRS) total scores. At the end of 
the trial, significantly more patients treated with sertindole 
20 mg/day than with placebo were “very much improved” 
(20% vs 3%; P , 0.05) considering Clinical Global Impres-
sion (CGI) scores. No statistically significant differences were 
found on the outcome measures for sertindole at doses of 8 
and 12 mg/day.45 Sertindole has been compared to haloperidol 
in two short-term46,47 and one long-term studies.48
In a multicenter, double-blind, placebo-controlled study 
by Zimbroff et al,46 497 hospitalized patients with schizophre-
nia and active psychosis were randomized to receive sertin-
dole 12, 20 or 24 mg/day, haloperidol 4, 8 or 16 mg/day, or 
placebo for an 8-week period. Measures of efficacy included 
the Positive and Negative Syndrome Scale (PANSS), the 
Scale for the Assessment of Negative Symptoms (SANS), 
the Clinical Global Impression (CGI) scale, and the Brief 
Psychiatric Rating Scale (BPRS). Three rating scales were 
used to assess EPS, as well as the occurrence of adverse 
events. Both sertindole and haloperidol were significantly 
more effective than placebo in the treatment of psychosis, 
as documented by improvements from baseline in PANSS 
and BPRS total scores at the end of the trial. Sertindole and 
haloperidol were equally effective, with the best results seen 
with the 20 mg/day dose of sertindole and the 8 mg/day dose 
of haloperidol.
Another multicenter, double-blind phase III trial,47 
involved 617 patients who were randomized to receive 
sertindole 8, 16, 20 or 24 mg/day or haloperidol 10 mg/day 
for 8 weeks. The sertindole 8 mg/day dose was chosen as a 
‘pseudo-placebo’. A significant reduction in PANSS total 
score was observed with sertindole 16 mg/day (by 23.8 points 
from baseline) and with haloperidol 10 mg/day (by 
22.8 points from baseline) compared to recipients of the 
sub-  therapeutic 8 mg/day dose of sertindole. In this study, 
sertindole 16 mg/day was at least as effective as the two 
higher doses. The results of these two comparative trials 
with haloperidol have suggested that sertindole was more 
effective against negative symptoms; moreover, sertindole 
16 mg/day was as efficacious as 20 mg/day, suggesting 
that the initial titration should be made to 16 mg/day. They 
also confirm that 8 mg/day was suboptimal with respect to 
efficacy.46,47 Additional evidence provided from the over-
mentioned studies is that sertindole 24 mg/day did not appear 
to be any more efficacious than 20 mg/day, the recommended 
prescribed dose range is 16–20 mg/day. The longer term effi-
cacy of sertindole was assessed in a double-blind, 12-month 
trial comparing 24 mg/day sertindole with 10 mg/day halo-
peridol in 282 outpatients with schizophrenia.48 At primary 
endpoint, time to treatment failure was numerically superior 
in sertindole-treated patients compared to haloperidol-treated 
patients, even if this difference did not reach statistical sig-
nificance. After 2 months of treatment, PANSS total score 
significantly decreased from baseline in sertindole group 
more than in haloperidol group (P , 0.05), although non 
statistically significant differences between groups were 
found after 12 months of treatment. Moreover, at 1-year 
follow-up, more haloperidol patients had left the study due 
to: any reason, adverse events and lack of efficacy, suggest-
ing better compliance for the sertindole compared with the 
haloperidol group.
A double-blind, parallel-group, flexible-dose, multicenter 
study compared the efficacy and tolerability of sertindole 
(12–24 mg/day; n = 98) with risperidone (4–10 mg/day; Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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n = 89) in 187 out- and inpatients with various subtypes of 
schizophrenia who had to be at least moderately ill. The study 
terminated prematurely because of the temporary withdrawal 
of sertindole from the European Union market; however, 
although early termination reduced the power of the study, 
some significant between-group differences emerged. After 
12 weeks of treatment, improvements in positive and negative 
symptoms were seen in both treatment groups. Sertindole-
treated patients had a greater reduction in PANSS negative 
subscale scores. However, data for leaving the study early 
were available but the total was high (35.8%). Adverse effects 
were only reported if . 5% occurrence.49
The recent observational NICHE study was a retrospec-
tive, single-arm, observational crossover study designed to 
evaluate complementary benefit/risk during the temporary 
suspension of the marketing authorizations for sertindole. 
The study included 344 patients who had two nonconsecutive 
treatment periods with sertindole. From the patients included 
in this study, around 17% followed four treatment periods. 
From the remaining patients, around 45% followed three 
treatment periods and around 38% followed two treatment 
periods. The results showed that a subset of patients switched 
to sertindole had an improvement in their clinical symptoms, 
as documented by the decrease in the number and duration 
of hospitalizations, as well as suicide attempts.50
Leucht et al51 have recently conducted a meta-analysis 
comparing nine second-generation antipsychotics with first-
generation drugs for overall efficacy, positive, negative, and 
depressive symptoms, relapse, quality of life, extrapyramidal 
side-effects, sedation, and weight gain. Results showed that 
five second-generation drugs (aripiprazole, quetiapine, sertin-
dole, ziprasidone, and zotepine) were not significantly dif-
ferent from first-generation antipsychotics in their effects on 
overall, positive, and negative symptoms, whereas   clozapine, 
amisulpride, olanzapine, and risperidone, were more effi-
cacious than first-generation drugs. Olanzapine (relative 
risk RR = 0.67; 95% confidence interval CI: 0.49–0.92), 
risperidone (RR = 0.74, 95% CI: 0.63–0.87), and sertindole 
(RR = 0.17; 95% CI: 0.04–0.73) proved to be significantly 
better than first-generation drugs on relapse prevention. With 
regard to quality of life, only clozapine (Hedge’s g = -0.24; 
95% CI: –0.46–0.01; P = 0.039), sertindole (Hedge’s 
g = -0.44; 95% CI: -0.483–0.05; P = 0.027), and amisulpride 
(Hedge’s g = -0.31; 95% CI: -0.60–0.03; P = 0.030) were 
better than first-generation drugs.51
The cited studies documented that sertindole is as 
effective as haloperidol and risperidone in the treatment of 
positive symptoms, but it may be more effective than these 
agents in the treatment of negative symptoms. These results 
need to be confirmed by further studies, as no randomized 
evidence   compares sertindole with other second   generation 
  antipsychotic drugs such as amisulpride, aripiprazole, clo-
zapine, olanzapine, quetiapine, ziprasidone or zotepine, as 
recently suggested by Komossa et al52 whose review was 
based on strict inclusion criteria with sensitivity analyzes 
in order to exclude studies with potentially skewed data 
and probable sources of bias, including selective report-
ing, incomplete outcome data, randomization and blinding 
methods.
Cognitive symptoms
As previously reported in the Pharmacological Profile sec-
tion, sertindole has no effect on muscarinic or histaminic 
H1 receptors, and, as a result, is not associated with anticho-
linergic side effects or sedation.53 A 12-week, randomized 
double-blind study has compared the effect of sertindole 
(10 to 24 mg/day) and haloperidol on cognitive functioning 
in 40 patients with schizophrenia. Neurocognitive assess-
ment included elementary cognitive processes (reaction 
time), working memory (digit span), and executive function 
(Wisconsin Card Sorting test). The results evidenced that 
sertindole was superior to haloperidol in most of the applied 
tasks after a short (4-week) as well as an extended (12-week) 
treatment period. The beneficial effects observed with sertin-
dole also seemed to be specific to cognitive independently 
of motor function.54 In this trial, however, a potential bias 
cannot be excluded, as a number of studies reported that 
first-generation antipsychotics, like haloperidol, were not 
effective in cognitive impairment,55 and they could even 
worsen cognitive functions.56,57 Moreover, further caution in 
the interpretation of the results obtained by Gallhofer et al54 
is needed, as the haloperidol group was also receiving anti-
cholinergic medication.
Another proposed mechanism underlying cognitive 
dysfunction and negative symptoms in schizophrenia is 
dopaminergic hypofunction in the prefrontal cortex (PFC).58 
Sertindole, as well as risperidone, markedly increased 
the extracellular levels of DA in medial PFC and nucleus 
accumbens of conscious rats; differently from risperidone, 
sertindole also enhanced extracellular levels of acetylcoline 
(ACh) and glutamate (Glu) in the rat mPFC.20 It has been 
hypothesized that potentiation of insufficient dopaminergic 
and glutamatergic transmission and strengthening of the cho-
linergic transmission in the PFC may explain the beneficial 
effects of sertindole on cognitive function in patients with 
schizophrenia,20,54 and the superior effect against negative Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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symptoms compared to risperidone reported in a clinical 
study on sertindole and risperidone.49
A recent PET (18F)-fluorodeoxyglucose (FDG) and 
magnetic resonance imaging (MRI) study on fifteen patients 
with schizophrenia receiving sertindole up to 24 mg/day 
or haloperidol up to 16 mg/day under a blind, cross-over 
condition, showed that sertindole, compared to haloperidol, 
had an activating function in the dorsolateral and anterior 
prefrontal cortex. Comparison of unmedicated patients and 
normal controls indicated that sertindole tended to change 
the relative metabolic rate of frontal regions in the direction 
of normal values.59 However, a major limitation of trials 
addressing the effect of sertindole on cognitive impairment 
in schizophrenia is that haloperidol was the comparator drug 
in most of the studies; consequently, the effective role of 
sertindole in treating cognitive dysfunctions has been incom-
pletely explored, and comparisons with second-generation 
drugs are needed.
Safety and tolerability
Sertindole safety profile has been evaluated in several 
clinical trials and large epidemiological studies involved 
in post-marketing surveillance programme.60–64 Additional 
information is provided in the product monograph.38
Common adverse events and overdose
Results from a safety database of approximately 2500 patients 
treated with sertindole in clinical trials evidenced that 89% 
of patients reported at least one treatment-emergent adverse 
event. The most commonly reported adverse events asso-
ciated with sertindole treatment were headhache (33.8% 
of patients), insomnia (31.3%), rhinitis/nasal congestion 
(28.5%), and, in male patients, decreased ejaculatory volume 
(21.8%). Sertindole is not associated with sedation; with 
regard to anticholinergic effects, dry mouth and constipation 
occurred in $10% of patients. These adverse events (AEs) 
did not appear to be dose-related.65 A relationship with sertin-
dole dose was observed for orthostatic hypotension, whose 
incidence was higher during the titration phase and propor-
tionally increased with increasing sertindole dose; 13% of 
patients treated with sertindole 24 mg/day vs 5% of patients 
treated with 8 mg/day (P , 0.05) experienced this AE.47 In 
the same trial, discontinuation rates due to AEs were low 
(#0.4%); nevertheless, 3.2% of male patients chose to stop 
treatment because of the sexual adverse event of decreased 
ejaculatory volume (DEV).47 The mechanism of a reduction 
in ejaculation volume during treatment with sertindole, a 
side-effect usually not associated with erectile disturbances or 
decreases in libido, is as yet not precisely known; this effect 
might be due to the α1 noradrenergic antagonistic properties 
of sertindole, and it probably does not involve retrograde 
ejaculation as no semen could be detected in the urine after 
orgasm.45 An alternative mechanism has been suggested 
involving calcium channels on the vas deferens as, in vitro, 
contractions of the vas deferens are known to be affected 
by calcium channel antagonists. Sertindole, such as other 
antipsychotics, has the property to block sodium and calcium 
influx channels,66 so this may contribute to DEV .
Experience with sertindole in acute overdose is limited; 
the drug appears to be relatively safe in overdose on its own, 
as patients taking estimated dosages up to 840 mg have recov-
ered without sequelae. A recent case-report evidenced that 
sertindole and fluoxetine overdose had a benign outcome;67 
however, fatal cases have occurred.38 Reported signs and 
symptoms of overdose were dyspnea, somnolence, slurred 
speech, tachycardia, hypotension, transient AV-block and 
QT-c prolongation; cases of Torsades de Pointes (TdP) have 
been observed, often when sertindole was combined with 
other drugs known to induce TdP. In overdose cases, due to 
the long half-life of sertindole in humans (3–5 day), and its 
QT prolongation capacity, therapeutic drug monitoring would 
be useful to follow the sertindole concentrations.68
ePS and akathisia
Data provided by clinical trials suggest that sertindole 
may produce EPS comparable to placebo. As assessed by 
Simpson-Angus Rating Scale (SAS), Barnes Akathisia 
Scale (BAS), and Abnormal Involuntary Movements Scale 
(AIMS), there were no statistically significant differences 
between sertindole (8–24 mg/day mg) and placebo for the 
incidence of EPS, use of medication to avoid extrapyra-
midal symptoms, akathisia, cogwheel rigidity, hypertonia 
and tremor. This was in sharp contrast to haloperidol 
(4–16 mg/day), which showed worsening in most of the 
EPS and akathisia scales.45–48 In the multicenter, 8-week, 
placebo-controlled trial by Zimbroff et al,46 the incidence of 
EPS was reported in 13.2%–23.6% of patients treated with 
sertindole (12–24 mg/day) compared with 27.4% of those 
given placebo, and with 43.7%–55.7% (P , 0.05) of patients 
treated with haloperidol (4–16 mg/day). The long-term halo-
peridol-controlled trial substantiated the favorable safety 
profile of sertindole, as a significantly lower incidence of 
akathisia (14% vs 24%), tremor (9% vs 21%), and hypertonia 
(9% vs 18%) was reported in patients treated with sertindole 
(24 mg/day) compared with those treated with haloperidol 
(10 mg/day).48 Lewis et al,69 in their meta-analysis of two Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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haloperidol-controlled trials,46,48 noted that the incidence 
of movement disorders was less frequent with sertindole 
(24 mg/day) than with haloperidol (10 mg/day), and not 
significantly different from placebo. Regarding risk ratio, 
sertindole 24 mg/day had a statistically significant lower 
risk than haloperidol 10 mg/day of akathisia (relative risk 
0.47; P = 0.0004), hypertonia (0.45; P = 0.003), and tremor 
(0.36; P = 0.00009).
The short-term, double-blind, risperidone-controlled trial 
by Azorin et al,49 showed that 19% of patients treated with 
sertindole vs 28% of those given risperidone reported EPS-
related AEs, although this difference did not reach statistical 
significance.
These limited data suggest that akathisia and parkin-
sonism may occur less frequently with sertindole than with 
risperidone. However, relatively high risperidone dose ranges 
of 4 to 10 mg/day (mean 6.6 mg/day) in the over-mentioned 
study must be taken into account.52
Long-term treatment with antipsychotic drugs, especially 
at high dosages, is associated with the risk of tardive dyskine-
sia (TD). Regarding sertindole, data on the potential risk for 
TD are still lacking, because of the limited duration of clinical 
trials and follow-ups. However, based on the low incidence 
of parkinsonism and akathisia with sertindole in clinical tri-
als, it may be hypothesized that this drug might have a low 
incidence of TD with long-term use. In animal models of 
TD, the chronic administration of sertindole or olanzapine 
did not produce a significant incidence of rat oral chewing 
movements, whereas chronic haloperidol treatment typically 
produces late-onset, purposeless oral chewing movements 
in laboratory rats with a prevalence of 60%. To the extent 
that this rat condition can be seen to model human TD, these 
animal results may predict low TD liability of sertindole and 
olanzapine chronic use.70
A trial including 151 patients switched from conventional 
antipsychotics to sertindole showed that three out of four 
patients who had developed tardive dyskinesia, dystonia 
and/or akathisia, apparently recovered from the movement 
disorders after switching to sertindole; in one patient, 
sertindole monotherapy was not sufficient to reduce the 
movement effects, but combination treatment with tetra-
benazine resulted in a greater reduction in extrapyramidal 
symptoms.71
The meta-analysis by Leucht et al51 showed that all 
second-generation antipsychotics were associated with much 
fewer EPS than haloperidol; however, with the exception of 
clozapine, olanzapine, and risperidone, second-generation 
drugs, including sertindole, have not been shown to be 
better than low-potency first-generation antipsychotics 
with regard to EPS. Furthermore, amisulpride, clozapine, 
olanzapine, quetiapine, risperidone, sertindole and zotepine 
were   associated with more weight gain than was haloperidol, 
whereas aripiprazole and ziprasidone were not.
endocrine and metabolic side effects
In addition to EPS, important AEs associated with atypical 
antipsychotics are the drugs’ prolactin profile, weight gain, 
and alteration of glucose and lipid metabolism. Sertindole 
does not cause clinically significant increases in prolactin, 
in short- or long-term clinical studies.45,47,48 Similarly to 
other atypical antipsychotics, sertindole appears to induce a 
moderate weight gain, presumably related to the high affinity 
for 5-HT2C receptors. In the placebo-controlled clinical trials, 
there was a statistically significant greater mean weight gain 
among participants taking sertindole (20 mg, mean weight 
gain of 3.3 kg) as compared to placebo (mean weight gain 
of 0.8 kg; P , 0.05).69
According to Hale et al,47 at six weeks, all of the sertin-
dole groups (8, 16, 20 or 24 mg/day) showed an increase 
in body weight from baseline to final evaluation ranging 
from 1.3 kg to 1.9 kg, all of which represented a statisti-
cally significant different weight change than that recorded 
for the haloperidol treatment group (-0.1 kg). In the long-
term trial, data on the incidence of weight gain were taken 
into account: at one year, a significantly greater number of 
sertindole treated participants (n = 19/141) were reported 
to have gained weight as compared to haloperidol treated 
participants (n = 3/141). Over one year of treatment with 
sertindole 24 mg/day, a mean weight gain of 4.6 kg from 
baseline was observed.48 In the double-blind, risperidone-
controlled trial, patients in both treatment groups showed 
a small increase in weight (sertindole, 2.1 ± 3.9 kg; ris-
peridone, 1.5 ± 3.7 kg) and body mass index (sertindole, 
0.7 ± 1.3; risperidone, 0.5 ± 1.2) with no significant differ-
ence between the two treatments. Nevertheless, there was a 
significant difference for the change in weight from baseline 
in kg, favoring risperidone.49
The multicenter, multinational, cohort European Post-
marketing Observational Sertindole (EPOS) Study, was 
designed to compare the safety of treatment with sertindole vs 
other antipsychotics.64 During the first 4 weeks of sertindole 
treatment 650 (62%) of the 1,050 patients remaining in the 
cohort experienced at least one AE; after 4 weeks, a slight 
increase was observed in the number of metabolic and 
nutritional disorder, and weight increase was observed in 
6% of patients.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Data on the effect of sertindole on glucidic and lipidic 
metabolism are still sparse and incomplete. Minor increases 
in plasma levels of glucose, cholesterol and triglycerides 
have been reported in short-term studies;65 increased mean 
plasma cholesterol levels in one trial (P , 0.05 vs placebo) 
were documented.45
Cardiovascular side effects
The propensity of sertindole to prolong the QT interval is well 
recognized. The QT interval is an ECG measure that consists 
of both depolarization and repolarization, beginning with the 
onset of ventricular depolarization (Q wave) and ending with 
completion of repolarization (T wave). In clinical practice, 
its corrected form for heart rate (QTc) is used, since the 
QT interval shortens with increasing heart rates. Prolonged 
QTc interval increases the risk of cardiac arrhythmias and 
may predispose to the development of ventricular tachyar-
rhythmias such as TdP and ventricular fibrillation.72 TdP is 
a malignant ventricular arrhythmia that is associated with 
long QT intervals and is generally unresponsive to the usual 
antiarrhythmic drugs; it can progress to ventricular fibril-
lation and sudden death. QTc intervals are usually around 
400 msec in duration, and values below 440 are considered 
normal. The greater the duration, the more likely torsade de 
pointes becomes, but 500 msec has frequently been used as a 
cut-off because longer QTc interval measures are associated 
with substantially higher risk.
Sertindole showed a dose-dependent increase in the 
QTc interval that averaged 22 msec at usual therapeutic 
doses, whereas a QTc interval , 500 msec was observed 
in approximately 2% of 2194 sertindole-treated patients.73,74 
In a multicenter, double-blind, placebo-controlled study by 
Zimbroff et al,46 mean QTc changes for the sertindole 12-, 
20-, and 24-mg groups and placebo were 7/11 msec, 17/19 
msec, and 19/21 msec, and -5/-4 msec, respectively; how-
ever, no ECG changes could be related to clinical signs or 
symptoms (eg, syncope), and no arrhythmias (ie, TdP) were 
seen in any of the sertindole treatment groups. Moreover, 
QTc value of $ 500 was observed in 1% of the patients 
in the sertindole groups, whereas no patient in the placebo 
group had a QT or QTc interval that exceeded 500 msec at 
any point during the study.
In a long-term study,48 only one participant from the 
sertindole group (24 mg) had a QT interval that exceeded 
500 msec. However, 11 sertindole treated participants had 
QTc intervals of at least 500 msec, compared to none in 
the haloperidol treated group (8% vs 0%, P , 0.05). In the 
risperidone-controlled trial by Azorin et al,49 significantly 
more sertindole-treated patients reported QT prolongation 
(22.7% versus 4.5%); moreover, of the 12 (12%) prema-
ture drop-outs during sertindole treatment, six were due 
to QTc interval prolongation. However, although a close 
  relationship between drug concentration and the extent of 
QT   prolongation can often be observed, this does not mean 
that such a relationship is also present with respect to the 
risk for TdP; an electrophysiologic study of sertindole in a 
rabbit heart model of TdP showed that, despite the QT pro-
longation, the torsadogenic potential of sertindole seems to 
be remarkably low.14
Beyond sertindole, many conventional and atypical 
antipsychotics have been related to prolongation of QTc.75 
The most compelling evidence exists with thioridazine which 
has been reported to increase QTc about of 30 msec, followed 
by ziprasidone (15.9 msec), haloperidol (7.1 msec), quetia-
pine (5.7 msec), risperidone (3.6–3.9 msec), and olanzapine 
(1.7 msec).76 It is noteworthy that not all drugs that prolong 
the QTc interval produce TdP and sudden death; all drugs 
associated with fatal arrythmias and sudden death have in 
common the fact that they affect myocardial repolarization 
blocking the delayed rectifier potassium IKr,77,78 a channel 
expressed by the HERG gene.72 The low myocardium/plasma 
ratio, and the limited distribution to the myocardium of sertin-
dole, may limit its effective   concentration at Ikr sites.75
Generally, drug-induced arrhythmias are more likely to 
occur in patients with pre-existing QT prolongation, which 
may be congenital or due to many causes (myocardial disease, 
left ventricular hypertrophy, malnourishment, alcoholism, 
ischemia, or potassium depletion). Moreover, drug interac-
tions must be taken into account, as drugs with minimal QTc 
interval prolongation may interact with other compounds, 
competing for the same metabolic way.79 Recently, the 
role of QT interval as the only marker for estimation of a 
drug’s proarrhythmic risk has been questioned, as for QTc 
durations , 500 ms, the QTc interval lacks a clear correla-
tion with TdP risk; conversely, T-wave morphology changes 
(notches, asymmetry, and flatness) are associated with inhi-
bition of the IKr channel and might be more important than 
the QTc interval in predicting TdP occurrence. Prominent 
T-wave morphology changes occurred during sertindole treat-
ment and in some cases without concomitant prolongation 
of the QTc interval, have been found in an ECG study on 37 
schizophrenic patients who were taking sertindole 16 mg.80 
Further ECG results from the same sample have recently been 
published.81 Beyond T-wave morphology and QTc interval, 
other markers, including QTc dispersion and Tpeak-Tend, 
may better correlate with cardiac arrhythmia risk. QT disper-Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
196
Muscatello et al
sion (QTD; normal range = 40–60 ms, with QTD . 100 ms) 
is the interlead difference between the shortest and longest 
QTc interval on a 12-lead surface ECG, whereas Tpeak-Tend, 
whose normal range is 80–100 ms, consists in the time from 
the peak of the T-wave to the end of the T-wave. Results 
from the ECG study on 37 patients switched to sertindole 
showed that the increase in QTc interval (mean prolongation: 
20 ± 23 ms) induced by sertindole, was not associated with 
a proportional increase in QTD. TPTE, however, increased 
from 81 to 88 ms (P = 0.05), values still considered within 
the normal range of TPTE in healthy subjects and, probably, 
of limited clinical relevance.81
Until a wide experience in estimating the total cardiac 
safety of psychiatric drugs is reached, clinicians should 
be aware of cardiovascular side effects, especially for the 
patients at risk, such as elderly or subjects with pre-existing 
cardiovascular disease.
Suicide and mortality rates
Several postmarketing epidemiological studies have been 
conducted to better define sertindole safety profile and 
to identify all deaths during sertindole treatment and the 
causes thereof.50,60–64 The multicenter, multinational, cohort 
EPOS Study,64 aimed to compare the safety of treatment 
with sertindole vs other antipsychotics under normal clini-
cal practice conditions, was designed to include a total of 
12,000 patients recruited in 13 European countries, and to 
follow patients for at least one year of therapy. As a result 
of the temporary removal of sertindole from the market, the 
study was prematurely terminated on December 1998, less 
than 18 months after it had begun recruitment. A total of 
2,321 patients were enrolled (1,064 treated with sertindole 
and 1,257 treated with other antipsychotics) at 226 centers 
in ten European countries. As the study was prematurely 
terminated, only 140 patients (64 taking sertindole and 76 
taking other antipsychotics) completed the full observation 
period. The overall mortality rates were 1.45 deaths per 100 
patient-years of exposure (PYE) (95% CI: 0.53–3.16) in the 
sertindole group (n = 1053) and 1.50 deaths per 100 PYE   
(95% CI: 0.72–2.76) in the nonsertindole group (n = 1257). 
The deaths were categorized by cause into noncardiac, 
cardiac, uncertain cause, and suicide. Suicide was the 
most common cause of death in the sertindole group, with 
three completed suicides occurring from start of treatment 
up to five days after discontinuation; moreover, in the 
sertindole group, no fatal cardiac AEs occurred within the 
study period or 5 days of cessation of sertindole treatment. 
Noncardiac death was the most common cause of death in 
the nonsertindole group.
The European sertindole safety and exposure survey 
(ESES), a follow-up study of 8608 patients treated with sertin-
dole in six European countries, showed an overall mortality 
rate of 0.92 deaths per 100 PYE (95% CI: 0.64–1.35), with no 
excess cardiovascular deaths (0.35 deaths per 100 PYE; 95% 
CI: 0.17–0.65) and suicide (0.21 deaths per 100 PYE; 95% 
CI: 0.09–0.41). Serious nonfatal adverse events included QTc 
interval prolongation, arrhythmias, convulsions and suicide 
attempts (see Table 2). A nested case-control study included 
in this survey identified age, cardiovascular and metabolic 
disorders as risk factors for cardiac/sudden death in patients 
receiving sertindole.60
The sertindole safety survey (SSS) was a multicenter 
retrospective survey of 1,432 patients treated with sertindole 
in 11 European contries after its market suspension; the 
overall mortality rate was 0.51 deaths per 100 PYE (95% CI: 
0.23–0.97). When considering only exposure after market 
suspension of sertindole (1,396 PYE), the mortality rate was 
0.64 deaths per 100 PYE (95% CI: 0.30–1.22). Suicide rates 
were 0.11 deaths per 100 PYE (95% CI: 0.01–0.41) and 0.14 
deaths per PYE (95% CI: 0.02–0.52) after market removal of 
sertindole; sudden death rates were 0.17 deaths PYE (95% CI: 
0.04–0.50) before, and 0.21 deaths PYE (95% CI: 0.04–0.63) 
after market suspension of sertindole, respectively. Among 
non-fatal SAEs (4.95 per 100 PYE; 95% CI: 3.96–6.10)   
15 cases (0.85 per 100 PYE; 95% CI: 0.48–1.41) of QT 
prolongation with no clinical effects were reported.62
The Sertindole Cohort Prospective (SCoP) study was a 
prospective, randomized, partially blinded, active-controlled, 
multinational trial, major prospective post- marketing surveil-
lance study aimed to compare the safety of sertindole with 
that of risperidone under normal conditions of use in nearly 
10,000 schizophrenic patients. The first primary endpoint was 
all-cause mortality, and the second was hospitalization with 
arrhythmia; secondary endpoints included cause-specific 
fatal events, suicide attempts, hospitalizations, and treat-
ment duration. After taking either sertindole (n = 4,930) or 
Table 2 Mortality rates from clinical trials and european Safety 
and exposure Survey (eSeS)
Clinical trials ESES
Patients (n) 3031 8608
Deaths (n) 29 35
All-cause 
mortality/100 PYe (Ci)*
1.52 (0.96–2.13) 0.92 (0.64–1.35)
Cardiac mortality/100 PYe (Ci)* 0.31 (0.11-0.688) 0.35 (0.17–0.65)
*Ci = 95% Confidence Intervals.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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risperidone (n = 4,928) for one year, there were 64 deaths in 
the sertindole group and 61 deaths in the risperidone group; 
this difference in all-cause mortality was not statistically 
  significant. However, sertindole was associated with a five-
fold greater risk of sudden cardiac death than risperidone 
(HR = 5.1, 95% CI: 1.5–17.9).61,63
A retrospective cohort study recently evaluated the 
adjusted incidence of sudden cardiac death among current 
users of antipsychotic drugs in 44,218 and 46,089 baseline 
users of single typical and atypical drugs, respectively, and 
186,600 matched nonusers of antipsychotic drugs. The study 
did not include sertindole, as it has not yet been marketed 
in the United States. Results obtained showed that current 
users of typical and of atypical antipsychotic drugs had 
higher rates of sudden cardiac death than did nonusers of 
antipsychotic drugs, with adjusted incidence rate ratios of 
1.99 (95% CI: 1.68–2.34) and 2.26 (95% CI: 1.88–2.72), 
respectively. On the other hand, former users of antipsy-
chotic drugs had no significantly increased risk (incidence 
rate-ratio, 1.13; 95% CI: 0.98–1.30). For both conventional 
and atypical antipsychotics, the risk of sudden cardiac death 
increased with an increasing dose; moreover, there was a 
dose-response trend for each of the six frequently prescribed 
drugs (haloperidol, thioridazine, clozapine, olanzapine, 
quetiapine, and risperidone), a trend that was significant 
in the case of thioridazine (P = 0.005) and of borderline 
significance in the case of risperidone (P = 0.05).82
Tiihonen et al83 have recently concluded a population-
based cohort study (FIN11 study) consisting of an 11-year 
follow-up of mortality in 66881 Finnish patients with 
schizophrenia treated with first- and second-generation 
antipsychotics. The study did not include separate analysis 
for sertindole, as altogether aripiprazole, sertindole, and 
ziprasidone accounted for 0%–3% of all defined daily doses 
(DDDs) (0.45 million of 156.46 million). Results showed 
that the overall risk of death was lower (HR = 0.68; 95% CI: 
0.65–0.71; P , 0.0001) during the current use of any antip-
sychotic drug than it was with no antipsychotic use. The risk 
of death was significantly lower in patients with long-term   
(7–11 years) antipsychotic treatment than in those who 
had not used any antipsychotic drugs during follow-up 
(HR = 0.81; 95% CI: 0.77–0.84; P , 0.0001). Furthermore, 
no signs of increased risk of death from ischemic heart 
disease were noted after 7–11 years of cumulative exposure 
to antipsychotic treatments. Comparisons of specific antip-
sychotics versus perphenazine showed that current use of 
quetiapine, haloperidol, and risperidone were associated with 
an increased mortality (41%, 37%, and 34%, respectively) 
and clozapine with a reduced mortality (-26%), suggesting 
that the increase in the use of second-generation antipsy-
chotics (from 13% to 64% during 1996–2006), rather than 
first-generation drugs, did not have a harmful effect on life-
expectancy of patients with schizophrenia, with the possible 
exception of quetiapine and risperidone.
Conclusion
Sertindole is a second-generation antipsychotic with a pecu-
liar pharmacological and clinical profile. It has recently been 
reintroduced in the market in several European countries for 
the treatment of schizophrenia under special safety conditions 
(ie, no first choice treatment, not for emergency treatment, 
ECG observation).
Like other second-generation antipsychotics, sertindole 
has a high affinity for serotonin 5-HT2A and 5-HT2C and α1 
adrenergic receptors; its affinity for dopamine D2   receptors 
is more pronounced in limbic rather than nigrostriatal sys-
tem. Due to its pharmacological characteristics, sertindole 
is expected to exert antipsychotic activity with limited risk 
of EPS. Moreover, sertindole showed modest affinity for 
H1-histaminergic and muscarinic receptors, thus suggesting 
a low potential to cause sedation or cognitive impairment. 
Sertindole is metabolized in the liver by the cytochrome P450 
isoenzymes CYP2D6 and CYP3A4 and has a plasma half-
life of approximately three days. The relatively long half-life 
in comparison to other atypical antipsychotics allows once 
daily administration and, theoretically, may result in low 
fluctuations in plasma and target receptor concentrations of 
the drug at steady-state.84
After a comprehensive clinical development programme 
leading to the introduction of sertindole in the EU in 1996, its 
temporary withdrawal from the market due to cardiovascular 
safety concerns, led to the need to examine potential cardiovas-
cular toxicity more than clinical efficacy; consequently, data on 
clinical efficacy are still limited. Although sertindole appeared 
to be generally well tolerated, more effective than placebo and 
at least as effective as haloperidol and risperidone on positive 
symptoms, the evidence is therefore very incomplete as studies 
were short-term and that long-term effectiveness studies are 
scarcely available, clearly limiting external validity.
Except for risperidone, no randomized trials have com-
pared sertindole with other second-generation antipsychotic 
drugs. Further “head-to-head” comparisons with other 
second-generation antipsychotic drugs are strongly needed. 
Preliminary data from pre-clinical, animal model and clinical 
studies suggest that sertindole should have a beneficial effect 
on schizophrenia-related cognitive disturbances.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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In clinical practice, sertindole can be administered orally 
once daily at the recommended starting dose of 4 mg/day, 
which can be titrated by increments of 4 mg after 4–5 days 
on each dose until the optimal daily maintenance dose, 
within the range of 12–20 mg, has been achieved. Doses 
should be halved for concomitant administration with strong 
CYP2D6 and CYP3A4 inhibitors. Renal impairment does not 
significantly change sertindole pharmacokinetics, reflecting 
its extensive hepatic metabolism. Thus, in patients with mild, 
moderate, and severe renal impairment, dosage adjustment is 
not necessary, while dose reduction is required in hepatically 
impaired patients, as the clearance of sertindole decreases 
in this population.
Information on the efficacy and safety of sertindole in 
special populations such as children and adolescents, elderly 
patients, and subjects with treatment-refractory schizophrenia 
is still limited or lacking.
Nevertheless, taking into account these weaknesses, the 
only available data demonstrated noninferiority to risperi-
done; sertindole may induce fewer movement disorders than 
risperidone – at least when the latter is given in relatively high 
doses (between 4 and 12 mg/day). However, sertindole may 
be associated with more QTc prolongation, weight change, 
and male sexual dysfunction. Moreover, data are limited on 
the effectiveness of sertindole in the maintenance treatment 
of schizophrenia.
With regard to the main tolerability and safety issues 
of sertindole, its effect on the QT interval is of concern. 
Like many antipsychotics, both conventional and atypical, 
sertindole can prolong the QTc interval. The length of the 
QTc interval has been associated with the risk of sudden 
death after myocardial infarction; although it is not proven 
that drug-induced QTc interval prolongation behaves in the 
same manner, it is thought to be a predictor for TdP episodes 
and is considered a risk factor for sudden cardiac death. 
Among atypical antipsychotics, sertindole, iloperidone,85 and 
ziprasidone, (which was not licensed in the UK because of 
concerns about potential cardiotoxicity), are the compounds 
associated with a greater risk of QTc prolongation. Among 
conventional antipsychotics, the most compelling evidence 
exists with thioridazine, that prolongs the QT interval, blocks 
the IKr channel, and is associated with numerous cases of 
TdP and an excess number of sudden death. Thioridazine 
prolongs the QTc interval about 30 msec, whereas the 
maximum prolongation of QTc interval with sertindole is 
20–22 msec (depending on dose). However, although QTc 
prolongation is a risk factor for serious arrythmias, there 
is considerable evidence in the literature that the relation 
between QTc prolongation and development of fatal arryth-
mias is not so direct. The low myocardium/plasma ratio, 
and the limited distribution to the myocardium of sertin-
dole, may limit its arrhythmogenic potential. Furthermore, 
cardiovascular risk is in fact associated with the risk of drug 
interaction and with the characteristics of patients exposed to 
the treatment in clinical practice. Patients with schizophrenia 
are considered a population at higher risk for sudden death 
independent of drug treatment. Before prescribing sertin-
dole, risk factors for drug-induced tachyarrythmias including 
female sex, cardiac hypertrophy, heart failure, bradycardia, 
electrolyte imbalances (mainly hypokalemia), congenital QT 
syndrome and drug interactions must be taken into account. 
The administration of sertindole, as recommended for other 
antipsychotics, is contraindicated if a QTC interval of more 
than 450 msec in males or 470 msec in females is observed 
at baseline. In order to substantially reduce cardiovascular 
risk, ECG monitoring is required before and during treat-
ment with sertindole. ECG monitoring should be carried 
out at baseline, upon reaching steady state after approxi-
mately three weeks, or when a dosage of 16 mg is reached, 
and again after three months of treatment. Furthermore, it 
is recommended to conduct additional ECG monitoring 
prior to and following any dosage change of sertindole, or 
of concomitant medication, which may increase sertindole 
concentration.
The potential for cardiac adverse events associated with 
sertindole is balanced by a tolerability profile characterized 
by the low liability to induce sedation, hyperprolactinemia, 
and EPS. With regard to tardive dyskinesia, there are no 
available data. During treatment with sertindole, a moder-
ate weight gain has been documented, although most of the 
studies evaluated the short-term period. Common side effects 
observed during sertindole treatment are headache, insomnia, 
rhinitis/nasal congestion and, in males, sexual dysfunctions, 
in terms of decreased ejaculatory volume. This latter effect 
may have implications for overall acceptability of treatment in 
male patients. Preliminary evidence suggests that sertindole 
is not associated with a increased risk of diabetes; however, 
its effect on serum glucose and lipid levels need further 
investigation.
It can be presumed that, as coadministration of psycho-
tropic drugs is relatively common in psychiatric clinical 
practice, sertindole will be reasonably prescribed in combina-
tion with other medications. Beyond the risk of synergistic 
effects with other drugs inducing QTc prolongation, whose 
use is contraindicated, the metabolic drug interaction profile 
of sertindole is far from being elucidated. Further studies are Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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necessary to define the mechanisms, severity, and duration of 
the interaction with those psychotropic drugs which are more 
likely to be co-administered, such as other antipsychotics, 
antidepressants, and mood stabilizers. A better understand-
ing of several pharmacological mechanisms (induction, 
competitive inhibition, or protein binding displacement) may 
elucidate whether there are any circumstances in which this 
interaction may have some clinical relevance.
At the present, it is difficult to define the place of sertin-
dole in the management of schizophrenia in the next few 
years. The prolonged marketing suspension of sertindole 
involved considerable medical and administrative restric-
tions on its supply and use, and had a significant impact on 
research. As a consequence, available data on its efficacy, 
safety, and tolerability profile are still sparse and incomplete. 
At this time, due to cardiovascular safety concerns, sertindole 
is available as a second-line choice for patients intolerant to 
at least one other antipsychotic agent. Moreover, considering 
its nonsedating properties, sertindole should not be used in 
emergency situations for urgent relief of symptoms in acutely 
disturbed patients. Based on available evidence from the 
literature, sertindole may reduce rates of relapse and risk of 
re-hospitalization and, furthermore, it may have a favorable 
effect on quality of life.
Second-generation antipsychotic drugs differ in 
many properties, including efficacy, side effects, and 
pharmacology. Within this context, sertindole appears to 
have an equivalent or slightly favorable profile compared 
to other antipsychotic drugs when taking into account 
relapse rate, quality of life, and the all cause mortality 
rate. Nevertheless, the total amount of available informa-
tion has not substantially changed in the recent years.84 
Further independent and appropriately powered clinical 
studies, mainly direct “head-to-head” comparisons with 
other second-generation antipsychotic agents, are needed 
to clinically define the role of sertindole in the treatment 
of schizophrenia.
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